To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

Inclusion Criteria:

• BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
• Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
• No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.

Exclusion Criteria:

• Allergy to liraglutide, orlistat or excipients
• Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
• Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
• Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
• Pregnant or lactating women
• Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).